Literature DB >> 27430959

Thrombin generation and cell-dependent hypercoagulability in sickle cell disease.

M F Whelihan1, M Y Lim1, M J Mooberry1, M G Piegore1, A Ilich1, A Wogu2, J Cai2, D M Monroe1, K I Ataga1, K G Mann3, N S Key4,5.   

Abstract

Essentials Sickle cell disease is increasingly being recognized as a chronic hypercoagulable state. Thrombin generation is elevated in the whole blood, but not the plasma of sickle cell patients. Whole blood thrombin generation inversely correlates to erythrocyte phosphatidylserine exposure. Acquired protein S deficiency is likely explained by binding of protein S to sickle red cells. Click to hear Dr Hillery discuss coagulation and vascular pathologies in mouse models of sickle cell disease.
SUMMARY: Introduction Sickle cell disease (SCD) is a hypercoagulable state with chronic activation of coagulation and an increased incidence of thromboembolic events. However, although plasma pre-thrombotic markers such as thrombin-anithrombin complexes and D-dimer are elevated, there is no consensus on whether global assays of thrombin generation in plasma are abnormal in patients with SCD. Based on our recent observation that normal red blood cells (RBCs) contribute to thrombin generation in whole blood, we hypothesized that the cellular components in blood (notably phosphatidylserine-expressing erythrocytes) contribute to enhanced thrombin generation in SCD. Methods Whole blood and plasma thrombin generation assays were performed on blood samples from 25 SCD patients in a non-crisis 'steady state' and 25 healthy race-matched controls. Results Whole blood thrombin generation was significantly elevated in SCD, whereas plasma thrombin generation was paradoxically reduced compared with controls. Surprisingly, whole blood and plasma thrombin generation were both negatively correlated with phosphatidylserine exposure on RBCs. Plasma thrombin generation in the presence of exogenous activated protein C or soluble thrombomodulin revealed deficiencies in the protein C/S anticoagulant pathway in SCD. These global changes were associated with significantly lower plasma protein S activity in SCD that correlated inversely with RBC phosphatidylserine exposure. Conclusion Increased RBC phosphatidylserine exposure in SCD is associated with acquired protein S deficiency. In addition, these data suggest a cellular contribution to thrombin generation in SCD (other than RBC phosphatidylserine exposure) that explains the elevated thrombin generation in whole blood.
© 2016 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  anemia; erythrocyte; phosphatidylserine; protein S; sickle cell; thrombin

Mesh:

Substances:

Year:  2016        PMID: 27430959     DOI: 10.1111/jth.13416

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  19 in total

Review 1.  Red blood cells in thrombosis.

Authors:  James R Byrnes; Alisa S Wolberg
Journal:  Blood       Date:  2017-08-15       Impact factor: 22.113

2.  High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease.

Authors:  Erica M Sparkenbaugh; Malgorzata Kasztan; Michael W Henderson; Patrick Ellsworth; Parker Ross Davis; Kathryn J Wilson; Brandi Reeves; Nigel S Key; Sidney Strickland; Keith McCrae; David M Pollock; Rafal Pawlinski
Journal:  J Thromb Haemost       Date:  2020-08-27       Impact factor: 5.824

Review 3.  Red blood cells: the forgotten player in hemostasis and thrombosis.

Authors:  J W Weisel; R I Litvinov
Journal:  J Thromb Haemost       Date:  2019-01-07       Impact factor: 5.824

4.  Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease.

Authors:  Camille Faes; Anton Ilich; Amandine Sotiaux; Erica M Sparkenbaugh; Michael W Henderson; Laura Buczek; Joan D Beckman; Patrick Ellsworth; Denis F Noubouossie; Lantarima Bhoopat; Mark Piegore; Céline Renoux; Wolfgang Bergmeier; Yara Park; Kenneth I Ataga; Brian Cooley; Alisa S Wolberg; Nigel S Key; Rafal Pawlinski
Journal:  Blood       Date:  2019-04-05       Impact factor: 22.113

5.  Rapid degradation of protein tyrosine phosphatase 1B in sickle cells: Possible contribution to sickle cell membrane weakening.

Authors:  Panae Noomuna; John M Hausman; Ruhani Sansoya; Theodosia Kalfa; Mary Risinger; Philip S Low
Journal:  FASEB J       Date:  2022-06       Impact factor: 5.834

Review 6.  Epidemiology and prevention of venous thromboembolism.

Authors:  Pamela L Lutsey; Neil A Zakai
Journal:  Nat Rev Cardiol       Date:  2022-10-18       Impact factor: 49.421

7.  Inflammation in sickle cell disease.

Authors:  Nicola Conran; John D Belcher
Journal:  Clin Hemorheol Microcirc       Date:  2018       Impact factor: 2.375

Review 8.  Therapeutic strategies for sickle cell disease: towards a multi-agent approach.

Authors:  Marilyn J Telen; Punam Malik; Gregory M Vercellotti
Journal:  Nat Rev Drug Discov       Date:  2019-02       Impact factor: 84.694

9.  Comparison of the clinical course of COVID-19 infection in sickle cell disease patients with healthcare professionals.

Authors:  Can Boğa; Süheyl Asma; Göksel Leblebisatan; Nazan Şen; Anıl Tombak; Yusuf Ziya Demiroğlu; Mahmut Yeral; Şule Akın; Hasan Yeşilağaç; Mehmet Ali Habeşoğlu; Anış Arıboğan; Mutlu Kasar; Aslı Korur; Hakan Özdoğu
Journal:  Ann Hematol       Date:  2021-05-25       Impact factor: 3.673

10.  D-Dimer in African Americans: Whole Genome Sequence Analysis and Relationship to Cardiovascular Disease Risk in the Jackson Heart Study.

Authors:  Laura M Raffield; Neil A Zakai; Qing Duan; Cecelia Laurie; Joshua D Smith; Marguerite R Irvin; Margaret F Doyle; Rakhi P Naik; Ci Song; Ani W Manichaikul; Yongmei Liu; Peter Durda; Jerome I Rotter; Nancy S Jenny; Stephen S Rich; James G Wilson; Andrew D Johnson; Adolfo Correa; Yun Li; Deborah A Nickerson; Kenneth Rice; Ethan M Lange; Mary Cushman; Leslie A Lange; Alex P Reiner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-09-14       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.